Derivation and external validation of dendritic cell-related gene signatures for predicting prognosis and immunotherapy efficacy in bladder urothelial carcinoma
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Urothelial Carcinoma /von 2022-12-12 / Front Immunol 2022;13:1080947Dendritic cell vaccines improve the glioma microenvironment: Influence, challenges, and future directions
/in Dendritic Cells, Glioblastoma, International Publications /von 2022-12-04 / Cancer Med 2023 Mar;12(6):7207-7221Immunotherapy for the treatment of pediatric brain tumors: a narrative review
/in Brain Tumors in Children, Dendritic Cells, International Publications, Newcastle Disease Virus /von 2022-12-01 / Transl Pediatr 2022 Dec;11(12):2040-2056
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution